|
Kidney Diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Regucalcin down-regulation in rat kidney tissue after treatment with nephrotoxicants.
|
18805471 |
2008 |
|
Liver neoplasms
|
0.220 |
Biomarker
|
group |
RGD |
Gel-based proteomics of liver cancer progression in rat.
|
21683810 |
2011 |
|
Liver neoplasms
|
0.220 |
AlteredExpression
|
group |
BEFREE |
Regucalcin mRNA and protein expressions are also depressed in human hepatoma HepG2 cells, MCF-7 breast cancer cells, and prostate cancer LNCaP cells.
|
23692083 |
2013 |
|
Liver neoplasms
|
0.220 |
Biomarker
|
group |
BEFREE |
In this study we have cloned and characterized cDNA for regucalcin from human liver and human hepatoma cell line Hep G2 by screening and rapid amplification of cDNA ends (RACE).
|
10677570 |
2000 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Serum levels of regucalcin (RGN) and syntaxin 7 (STX7) were found to be lower in patients with both recurring tumors and a high Breslow's thickness (T-stage 3/4) compared to low thickness (T-stage 1/2) without disease recurrence.
|
28433799 |
2017 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Subsequently, transfection of lentivirus-mediated RGN into HeLa cells was conducted to study its function in tumor proliferation and metastasis.
|
31289533 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Tg-RGN rats displayed lower incidence of carcinogen-induced mammary gland tumors, as well as lower incidence of invasive forms.
|
25128811 |
2015 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Overexpression of regucalcin was found to suppress multiple signaling pathways including Akt, MAP kinase and SAPK/JNK, and NF-κB p65 and β-catenin along with increased p53, a tumor suppressor, and decreased K-ras, c-fos and c-jun.
|
27221776 |
2016 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
A higher regucalcin expression in the tumor tissues has been demonstrated to prolong the survival of patients with various types of cancer, including pancreatic cancer, breast cancer, liver cancer and lung adenocarcinoma.
|
29956741 |
2018 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
The loss of regucalcin expression in breast and prostate cancer cases and the regulation of its expression by sex steroid hormones suggest that it may be associated with development and progression of these human tumors.
|
19347872 |
2009 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Regucalcin expression was compared in 23 normal and 29 tumor samples of kidney cortex tissues of patients with clear cell RCC obtained through the Gene Expression Omnibus (GEO) database (GSE36895).
|
30387835 |
2019 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Overexpression of regucalcin was found to suppress signaling pathways including Akt, MAP kinase and SAPK/JNK, to increase the protein levels of p53, a tumor suppresser, and to decrease K-ras, c-fos and c-jun, a oncogene, by suppressing signaling pathways that are related to signaling of K-ras.
|
26935290 |
2016 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Moreover, overexpression of regucalcin caused decreases in the oncogenes c-fos and c-myc and elevation of the tumor suppressers p53 and Rb.
|
28181135 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The upregulation of regucalcin (RGN) in various tumor cell types inhibits the progression of cancer.
|
31289533 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy.
|
31718698 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Regucalcin (RGN) is a calcium-binding protein, which has been shown to be underexpressed in cancer cases.
|
25128811 |
2015 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
A higher regucalcin expression in the tumor tissues has been demonstrated to prolong the survival of patients with various types of cancer, including pancreatic cancer, breast cancer, liver cancer and lung adenocarcinoma.
|
29956741 |
2018 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Regucalcin, which plays a pivotal role as an inhibitor of signal transduction and transcription activity, has been suggested to act as a suppressor of human cancer.
|
27221776 |
2016 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In a word, SMP30 can inhibit the proliferation and invasion of human hepatoma cells and thus can be regarded as a cancer suppressive factor.
|
24606440 |
2014 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy.
|
31718698 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Regucalcin (RGN) is a calcium-binding protein, which has been shown to be underexpressed in cancer cases.
|
25128811 |
2015 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
A higher regucalcin expression in the tumor tissues has been demonstrated to prolong the survival of patients with various types of cancer, including pancreatic cancer, breast cancer, liver cancer and lung adenocarcinoma.
|
29956741 |
2018 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Regucalcin, which plays a pivotal role as an inhibitor of signal transduction and transcription activity, has been suggested to act as a suppressor of human cancer.
|
27221776 |
2016 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
The upregulation of regucalcin (RGN) in various tumor cell types inhibits the progression of cancer.
|
31289533 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
In a word, SMP30 can inhibit the proliferation and invasion of human hepatoma cells and thus can be regarded as a cancer suppressive factor.
|
24606440 |
2014 |